US Stock Insider Trading | ProMIS Neurosciences disclosed one insider trading transaction on February 23

2026-02-24 22:39:20

On February 23, 2026, ProMIS Neurosciences (PMN) disclosed one insider transaction. Executive Johanne Kaplan purchased 1,629 shares on February 19, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Executive	Johanne Kaplan	February 19, 2026	Buy	1,629	15.35	$25,000
February 5, 2026	Shareholder	Max A. Milbury	February 3, 2026	Buy	6,595	12.13	$80,000
February 5, 2026	Executive	Johanne Kaplan	February 3, 2026	Buy	2,060	12.13	$25,000
February 5, 2026	Director	Neil Cashman	February 3, 2026	Buy	4,122	12.13	$50,000
February 5, 2026	Director	Neil K. Warma	February 3, 2026	Buy	6,183	12.13	$75,000
February 5, 2026	Shareholder with >10%	ABG Management Ltd.	February 3, 2026	Buy	700,700	12.13	$8,500,000
February 5, 2026	Director	Patrick D. Kirwin	February 3, 2026	Buy	3,050	12.13	$37,000
October 6, 2025	Shareholder	Max A. Milbury	October 3, 2025	Buy	30,400	0.49	$1,490
February 12, 2025	Director	Neil Cashman	February 10, 2025	Buy	15,000	0.97	$14,600
September 24, 2024	Director	Madge K. Shafmaster	September 20, 2024	Buy	60,000	1.25	$75,100

[Company Information]

ProMIS Neurosciences Inc. was incorporated under the Canada Business Corporations Act on January 23, 2004, and is located at 1920 Yonge Street, Toronto, Ontario. The company is applying its proprietary platform technology to develop antibody therapies, therapeutic vaccines, and other antibody-based treatment combinations for neurodegenerative diseases and other misfolded protein disorders, including Alzheimer’s disease, multiple system atrophy, and amyotrophic lateral sclerosis. The company also plans to research other synucleinopathies, including Parkinson’s disease and Lewy body dementia, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. These diseases share a common biological cause—misfolded proteins that, if not corrected, lose their normal function, become toxic, and kill neurons, leading to disease. ProMIS’s platform exemplifies advances in drug discovery through computational power, computer-aided discovery, and artificial intelligence.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.